CA
BBIO icon

Continuum Advisory’s BridgeBio Pharma BBIO Stock Holding History

Continuum Advisory’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.61K Buy
+35
New +$2.45K ﹤0.01% 1664
2024
Q2 		– Sell
-34
Closed -$977 – 1709
2024
Q1 		$977 Buy
+34
New +$1.16K ﹤0.01% 1471

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Continuum Advisory's BBIO Position: Q2 2026 in Review

Continuum Advisory opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 35 shares worth $2.61K. The stake represents ﹤0.01% of the portfolio and ranks #1664 among its holdings. This is a return to the name: Continuum Advisory previously reported a position in BBIO as recently as Q1 2024.

Continuum Advisory first reported a position in BBIO in Q1 2024 and has held it in 2 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Continuum Advisory held 35 shares of BridgeBio Pharma worth $2.61K as of Q2 2026.
  • BridgeBio Pharma was a new Continuum Advisory position in Q2 2026.
  • BridgeBio Pharma made up ﹤0.01% of Continuum Advisory's portfolio in Q2 2026, its #1664 holding.
  • Continuum Advisory first reported a position in BridgeBio Pharma in Q1 2024 and has held it in 2 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.